Loading…
Employees: 553
Size Shanghai Kinetic Medical (300326.SZ) is a China Health Care company (Medical Specialties) with a market value of $698M, the 3066th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.57 on 6 Nov 2026.
Performance Over six months the shares fell 7.5%, against -6.4% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 28.1% over the last twelve months (peer median +6.2%); the operating margin is 17.1% (peer median 11.0%).
Valuation It trades at 27.4× forward earnings against a peer median of 17.6× (5th most expensive of 15).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -2%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.9 points above its cost of capital (8.2% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥734M | CN¥960M | CN¥979M | CN¥949M | CN¥1.16B |
| Revenue growth | — | -2% | +3% | -18% | — |
| Gross profit | CN¥504M | CN¥468M | CN¥446M | CN¥444M | CN¥695M |
| EBITDA | n/a | CN¥142M | CN¥163M | CN¥158M | CN¥287M |
| Net income | CN¥269M | CN¥135M | -CN¥106M | CN¥113M | -CN¥21.3M |
| Free cash flow | CN¥249M | CN¥144M | CN¥94.6M | CN¥230M | CN¥203M |
| Capital expenditure | CN¥21.8M | CN¥66.2M | CN¥82.8M | CN¥53.8M | CN¥41.5M |
| Total debt | CN¥50.3M | CN¥54.2M | CN¥326M | CN¥197M | CN¥329M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300326.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.2% | -1.4% | 6th highest of 21 |
| 6-month return | -7.5% | -6.4% | 11th highest of 21 |
| Distance from 52-week high | -10.4% | -25.6% | 4th highest of 21 |
| Revenue growth (TTM) | -28.1% | +6.2% | lowest of 21 |
| Operating margin | 17.1% | 11.0% | 9th highest of 21 |
| Forward P/E | 27.4× | 17.6× | 5th most expensive of 15 |
| Growth the price implies (Req g, 7 yrs) | 8.1% | -0.3% | 7th most demanding of 15 |
| Growth delivered (Del g) | -1.9% | +12.8% | lowest of 15 |
| Hurdle (Req g minus delivered) | +10.0 pp | -10.9 pp | 3rd most demanding of 15 |
| ROIC minus cost of capital | +0.9 pp | +4.1 pp | 10th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 27.4× | 8.1% | -1.9% |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 50.9× | 29.1% | +6.8% |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 14.1× | -9.7% | +2.9% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $684M | -21% | -13% | 31% | 19.1× | -5.4% | +2.2% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 47.6× | n/a | n/a |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 32.4× | 13.5% | +13.3% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | n/a | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | n/a | -0.7% | +18.8% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |